BDBM683053 US12023331, Example 1::US12195462, Example 3::US20240307386, Compound Example 1

SMILES Fc1ccc(OCCCN2CC[C@H]3[C@@H](C2)c2cccc4NC(=O)CN3c24)cc1

InChI Key InChIKey=MXIJXDUPULMKIE-UHFFFAOYSA-N

Data  20 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 20 hits for monomerid = 683053   

Target5-hydroxytryptamine receptor 2A(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  8.30nMAssay Description:In general, the results are expressed as a percent of control specific binding: measured⁢specific⁢bindingcontrol⁢specific⁢bin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  8.30nMAssay Description:Receptor binding is determined for the Compounds of Examples 1, 2 and 3 (corresponding to Formula 1, Formula B and Formula A, respectively). The foll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  8.30nMAssay Description:In general, the results are expressed as a percent of control specific binding:measured⁢specific⁢bindingcontrol⁢specific⁢binding×100and as a percent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  8.30nMAssay Description:Receptor binding is determined for the Compound of Example 1, using the compound of Formula A as a control. The following literature procedures are u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/8/2024
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  11nMAssay Description:Receptor binding is determined for the Compounds of Examples 1, 2 and 3 (corresponding to Formula 1, Formula B and Formula A, respectively). The foll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  11nMAssay Description:In general, the results are expressed as a percent of control specific binding:measured⁢specific⁢bindingcontrol⁢specific⁢binding×100and as a percent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2025
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  11nMAssay Description:Receptor binding is determined for the Compound of Example 1, using the compound of Formula A as a control. The following literature procedures are u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/8/2024
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  11nMAssay Description:In general, the results are expressed as a percent of control specific binding: measured⁢specific⁢bindingcontrol⁢specific⁢bin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2025
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  50nMAssay Description:Receptor binding is determined for the Compound of Example 1, using the compound of Formula A as a control. The following literature procedures are u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/8/2024
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  50nMAssay Description:In general, the results are expressed as a percent of control specific binding:measured⁢specific⁢bindingcontrol⁢specific⁢binding×100and as a percent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2025
Entry Details
Go to US Patent

TargetSodium-dependent serotonin transporter(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  50nMAssay Description:In general, the results are expressed as a percent of control specific binding: measured⁢specific⁢bindingcontrol⁢specific⁢bin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2025
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  50nMAssay Description:Receptor binding is determined for the Compounds of Examples 1, 2 and 3 (corresponding to Formula 1, Formula B and Formula A, respectively). The foll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetD(2) dopamine receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  160nMAssay Description:Receptor binding is determined for the Compound of Example 1, using the compound of Formula A as a control. The following literature procedures are u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/8/2024
Entry Details
Go to US Patent

TargetD(2) dopamine receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  160nMAssay Description:In general, the results are expressed as a percent of control specific binding:measured⁢specific⁢bindingcontrol⁢specific⁢binding×100and as a percent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2025
Entry Details
Go to US Patent

TargetD(2) dopamine receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  160nMAssay Description:Receptor binding is determined for the Compounds of Examples 1, 2 and 3 (corresponding to Formula 1, Formula B and Formula A, respectively). The foll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent

TargetD(2) dopamine receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  160nMAssay Description:In general, the results are expressed as a percent of control specific binding: measured⁢specific⁢bindingcontrol⁢specific⁢bin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2025
Entry Details
Go to US Patent

TargetSodium-dependent serotonin transporter(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  590nMAssay Description:Receptor binding is determined for the Compound of Example 1, using the compound of Formula A as a control. The following literature procedures are u...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/8/2024
Entry Details
Go to US Patent

TargetSodium-dependent serotonin transporter(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  590nMAssay Description:In general, the results are expressed as a percent of control specific binding:measured⁢specific⁢bindingcontrol⁢specific⁢binding×100and as a percent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2025
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  590nMAssay Description:In general, the results are expressed as a percent of control specific binding: measured⁢specific⁢bindingcontrol⁢specific⁢bin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2025
Entry Details
Go to US Patent

TargetSodium-dependent serotonin transporter(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  590nMAssay Description:Receptor binding is determined for the Compounds of Examples 1, 2 and 3 (corresponding to Formula 1, Formula B and Formula A, respectively). The foll...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2025
Entry Details
Go to US Patent